Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation.

McDowell RS, Elias KA, Stanley MS, Burdick DJ, Burnier JP, Chan KS, Fairbrother WJ, Hammonds RG, Ingle GS, Jacobsen NE, Mortensen DL, Rawson TE, Won WB, Clark RG, Somers TC.

Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11165-9.

2.

Ipamorelin, the first selective growth hormone secretagogue.

Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH.

Eur J Endocrinol. 1998 Nov;139(5):552-61.

3.

Novel orally active growth hormone secretagogues.

Hansen TK, Ankersen M, Hansen BS, Raun K, Nielsen KK, Lau J, Peschke B, Lundt BF, Thøgersen H, Johansen NL, Madsen K, Andersen PH.

J Med Chem. 1998 Sep 10;41(19):3705-14.

PMID:
9733496
4.

A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.

Ankersen M, Johansen NL, Madsen K, Hansen BS, Raun K, Nielsen KK, Thogersen H, Hansen TK, Peschke B, Lau J, Lundt BF, Andersen PH.

J Med Chem. 1998 Sep 10;41(19):3699-704.

PMID:
9733495
5.
6.

Tripeptide growth hormone secretagogues.

Yang L, Morriello G, Pan Y, Nargund RP, Barakat K, Prendergast K, Cheng K, Chan WW, Smith RG, Patchett AA.

Bioorg Med Chem Lett. 1998 Apr 7;8(7):759-64.

PMID:
9871537
8.

The effects of growth hormone (GH)-releasing peptides on GH secretion in perifused pituitary cells of adult male rats.

Badger TM, Millard WJ, McCormick GF, Bowers CY, Martin JB.

Endocrinology. 1984 Oct;115(4):1432-8.

PMID:
6148232
9.

An extremely sensitive in vitro model for elucidating structure-activity relationships of growth hormone-releasing factor analogs.

Heiman ML, Nekola MV, Murphy WA, Lance VA, Coy DH.

Endocrinology. 1985 Jan;116(1):410-5.

PMID:
2856874
10.
11.

Design of biologically active, conformationally constrained GnRH antagonists.

Struthers RS, Tanaka G, Koerber SC, Solmajer T, Baniak EL, Gierasch LM, Vale W, Rivier J, Hagler AT.

Proteins. 1990;8(4):295-304.

PMID:
2091022
12.
13.

On the actions of the growth hormone-releasing hexapeptide, GHRP.

Bowers CY, Sartor AO, Reynolds GA, Badger TM.

Endocrinology. 1991 Apr;128(4):2027-35.

PMID:
2004615
14.

1H NMR structural analysis of human ghrelin and its six truncated analogs.

Silva Elipe MV, Bednarek MA, Gao YD.

Biopolymers. 2001 Dec;59(7):489-501.

PMID:
11745115
15.

Growth hormone-releasing peptides.

Ghigo E, Arvat E, Muccioli G, Camanni F.

Eur J Endocrinol. 1997 May;136(5):445-60. Review.

PMID:
9186261
16.

The development of 'impervious peptides' as growth hormone secretagogues.

Deghenghi R.

Acta Paediatr Suppl. 1997 Nov;423:85-7. Review.

PMID:
9401550
17.

Regulation of His-dTrp-Ala-Trp-dPhe-Lys-NH2 (GHRP-6)-induced GH secretion in the rat.

Mallo F, Alvarez CV, Benitez L, Burguera B, Coya R, Casanueva FF, Dieguez C.

Neuroendocrinology. 1993;57(2):247-56.

PMID:
8510800
18.
19.
20.

Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat.

Clark RG, Thomas GB, Mortensen DL, Won WB, Ma YH, Tomlinson EE, Fairhall KM, Robinson IC.

Endocrinology. 1997 Oct;138(10):4316-23.

PMID:
9322945

Supplemental Content

Support Center